Abstract: The present disclosure relates to methods and compositions, e.g., kits, for quantitatively detecting an antibody of a subject to an infectious organism. In some embodiments, the present disclosure provides for methods and compositions, e.g., kits, for quantitatively detecting a human antibody to SARS-CoV-2 polypeptide or S (spike) polypeptide. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.

Abstract: The present disclosure relates to methods and compositions, e.g., kits, for quantitatively detecting an antibody of a subject to an infectious organism. In some embodiments, the present disclosure provides for methods and compositions, e.g., kits, for quantitatively detecting a human antibody to SARS-CoV-2 polypeptide or S (spike) polypeptide. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.

Abstract: The present invention concerns compounds derived from the anaesthetic propofol that are useful as analgesics and methods of using the same. The compounds act as co-activators of strychnine-sensitive glycine receptors and may have greater activity at those glycine receptors than at GABAA.

Abstract: The invention provides extraction columns for the purification of an analyte (e.g., a biological macromolecule, such as a polypeptide or protein) from a sample solution, as well as methods for making and using such columns. The columns typically include a bed of extraction medium in a column. In some embodiments, the extraction columns employ modified pipette tips as column bodies. In some embodiments, the invention provides resins and methods that facilitate elution of analyte in a small volume of liquid. In some embodiments, the analyte is an active protein.

Abstract: The present invention concerns compounds derived from the anaesthetic propofol that are useful as analgesics and methods of using the same. The compounds act as co-activators of strychnine-sensitive glycine receptors and may have greater activity at those glycine receptors than at GABAA.

Abstract: The present application describes a method for normalizing for variations in signal intensity observed in a biomolecular binding assay carried out in a flow cell cartridge. Variations in signal intensity occur as a result of the effect of the surfaces of a flow cell cartridge on the laminar flow of reagent through the cartridge. In any individual reagent stream, fluid flows faster in the center of the stream and slower at the outer periphery of the stream due to contact of the reagent with the walls of the cartridge, creating a parabolic fluid flow profile. The present invention describes a method for normalizing or calibrating out the differences in intensity observed in different regions of interest on a single chip or similar reactions carried out in different cartridges, as a result of these differential fluid flow rates. Microarray chips having integrated calibration regions are also described.

Abstract: The invention provides extraction columns for the purification of an analyte (e.g., a biological macromolecule, such as a peptide, protein or nucleic acid) from a sample solution, as well as methods for making and using such columns. The columns typically include a bed of extraction media positioned in the column between two frits. In some embodiments, the extraction columns employ modified pipette tips as column bodies. The invention also provides methods for using the extraction columns including methods for varying parameters, such as the volume of sample loaded, the number of capture cycles performed, and the number or wash cycles performed to achieve a particular desired result.